Statin, Beyond Hyperlipidemia toward a Novel Agent for Hepatitis C

We read with great interest the article by malaguarnera et al. (1) in this issue of hepatitis monthly, in which the safety and efficacy of rosuvastatin plus interferon and ribavirin were evaluated in a randomized controlled trial. sustained viral response was observed in 40% of the standard-care group and 51% of the triple-therapy group, and this was associated with improvement of steatosis and fibrosis without causing side effects. despite the importance of this study, we think that the clinical implications extracted from this study deserve further evaluation. in particular, we question some components of the study design.